

Amendments to the Claims

Please cancel Claims 25, 26 and 27. Please amend Claims 1, 3 and 11. Please add new Claims 31 and 32. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently amended) A cell line which synthesizes and expresses on the cell surface Thomsen-Friedenreich antigen (TF), mucin 1 (MUC1), and glycoporphin, ~~wherein the TF is exposed~~ wherein the cell line is capable of inducing a humoral immune response against the TF antigen.
2. (Cancelled)
3. (Currently amended) The cell line of claim 1 which is selected from the group consisting of
 - (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606;
 - (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605;and
 - (c) subclones of (a) or (b) which synthesizes and express on the cell surface TF, MUC1, and glycoporphin, ~~wherein the TF is exposed~~ wherein the cell line is capable of inducing a humoral immune response against the TF antigen.
4. (Cancelled)
5. (Previously presented) The cell line of claim 1, comprising a vector which comprises a nucleic acid molecule.
6. (Original) The cell line of claim 5, wherein said nucleic acid molecule encodes at least one polypeptide of a polypeptide selected from the group consisting of a cytokine, MHC class I molecule, MHC class II molecule and costimulatory molecule, T cell epitope or multimers thereof, tumour antigen, hormone, sexual hormone, adjuvant, antibody or other molecules or fragments thereof having biological activity or any combination thereof.

7-10. (Cancelled)

11. (Currently amended) A composition comprising a cell line which synthesizes and expresses on the cell surface TF, MUC1, and glycophorin, ~~wherein the TF is exposed~~ wherein the cell line is capable of inducing a humoral immune response against the TF antigen.

12. (Previously presented) The composition of claim 11, which is a pharmaceutical or vaccine composition.

13-22. (Cancelled)

23. (Previously presented) The cell line of claim 1, wherein the glycophorin is asialoglycophorin.

24. (Previously presented) The cell line of claim 1, wherein the MUC1 is tumor-associated MUC1 (TA-MUC1).

25-27. (Cancelled)

28. (Previously presented) The cell line of claim 1, wherein the cell line is obtainable from the K562 cell line.

29. (Previously presented) The cell line of claim 1, wherein the cell line is obtainable by chemical mutagenesis.

30. (Previously presented) The cell line of claim 29, wherein the chemical mutagen is ethyl methanesulfonate (EMS).

31. (New) The cell line of claim 1, wherein the cell line is further capable of inducing a humoral immune response against MUC1 and asialoglycophorin.

32. (New) The cell line of claim 1, wherein the cell line is capable of inducing the humoral immune response against TF antigen in NMRI and/or NOD/SCID mice when administered at a dose of 5×10^6 cells/mouse.